Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases. Company news centers on its neuroscience portfolio, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's disease-related dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Recurring updates cover product revenue trends for Qelbree, GOCOVRI, ZURZUVAE, ONAPGO and other CNS therapies, quarterly financial results, collaboration and licensing revenue, investor conference participation, and pipeline activity for novel CNS product candidates such as SPN-820 in major depressive disorder.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Supernus Pharmaceuticals (Nasdaq: SUPN) plans to announce its first-quarter 2023 financial results on May 9, 2023, after market close. President and CEO Jack Khattar along with CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss these results and answer questions. The call will also be available via live webcast on the Company’s Investor Relations website. Supernus focuses on developing treatments for central nervous system (CNS) diseases, including approved products for conditions like epilepsy and Parkinson’s disease. The company also has a pipeline of novel CNS candidates aimed at various disorders.
Supernus Pharmaceuticals (Nasdaq: SUPN) has fully repaid its 0.625% Convertible Senior Notes due 2023, amounting to $402.5 million, along with $1.3 million in interest. The repayment was financed mainly using available cash and partially through a borrowing under its credit line. With this repayment, the 2023 Notes are no longer outstanding. Supernus continues to focus on developing treatments for CNS diseases, including epilepsy and Parkinson's disease, with ongoing development of novel product candidates.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced participation in two investor conferences in March 2023. The first is the Barclays Global Healthcare Conference on March 15, 2023, at the Loews Miami Beach Hotel, Florida. The second is the Jefferies Biotech on the Bay Summit on March 16, 2023, at The 1 Hotel South Beach, Florida. These events will feature management discussions focused on the company's biopharmaceutical products for central nervous system (CNS) diseases, including treatments for epilepsy and Parkinson's disease. Investors can arrange meetings with management through conference coordinators.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that CEO Jack Khattar will participate in a fireside chat and investor meetings at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:50 a.m. ET. The conference runs from March 6-8, 2023, at the Boston Marriott Copley Place. Interested investors can set up meetings through the Cowen conference coordinator. A live audio webcast of Khattar's presentation will be available on Supernus' Investor Relations website, with a replay accessible for 60 days post-conference. Supernus focuses on CNS disease treatments, including epilepsy and ADHD, with ongoing development of new therapies.